Karyopharm Therapeutics (NASDAQ:KPTI) Given New $8.00 Price Target at HC Wainwright

Karyopharm Therapeutics (NASDAQ:KPTI) had its price objective reduced by HC Wainwright from $15.00 to $8.00 in a report released on Wednesday,Benzinga reports. They currently have a buy rating on the stock.

Other research analysts also recently issued research reports about the stock. Cantor Fitzgerald initiated coverage on shares of Karyopharm Therapeutics in a research note on Thursday, February 5th. They issued an “overweight” rating on the stock. Piper Sandler restated an “overweight” rating and issued a $12.00 price objective on shares of Karyopharm Therapeutics in a report on Wednesday, December 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Karyopharm Therapeutics in a research report on Monday, December 29th. The Goldman Sachs Group set a $12.00 target price on Karyopharm Therapeutics in a research note on Wednesday, December 17th. Finally, Rodman & Renshaw upgraded Karyopharm Therapeutics to a “strong-buy” rating in a research note on Tuesday, March 10th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Karyopharm Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $14.86.

Karyopharm Therapeutics Price Performance

Shares of NASDAQ:KPTI opened at $5.21 on Wednesday. Karyopharm Therapeutics has a 1-year low of $3.51 and a 1-year high of $10.99. The business has a fifty day moving average price of $7.76 and a 200-day moving average price of $6.84. The company has a market capitalization of $95.55 million, a PE ratio of -0.31 and a beta of 0.13.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings results on Friday, February 13th. The company reported ($2.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.26) by $0.03. The firm had revenue of $34.08 million during the quarter, compared to the consensus estimate of $33.16 million. On average, sell-side analysts anticipate that Karyopharm Therapeutics will post -0.71 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of KPTI. Corient Private Wealth LLC purchased a new position in shares of Karyopharm Therapeutics during the 4th quarter valued at about $74,000. Baird Financial Group Inc. purchased a new stake in Karyopharm Therapeutics in the 2nd quarter worth approximately $45,000. State Street Corp increased its holdings in Karyopharm Therapeutics by 27.2% in the 4th quarter. State Street Corp now owns 58,942 shares of the company’s stock worth $434,000 after acquiring an additional 12,600 shares in the last quarter. Tudor Investment Corp ET AL bought a new stake in Karyopharm Therapeutics during the 4th quarter worth approximately $95,000. Finally, XTX Topco Ltd bought a new stake in Karyopharm Therapeutics during the 2nd quarter worth approximately $56,000. Hedge funds and other institutional investors own 66.44% of the company’s stock.

Key Karyopharm Therapeutics News

Here are the key news stories impacting Karyopharm Therapeutics this week:

• Positive Sentiment: SENTRY met the co‑primary endpoint for spleen‑volume reduction and the company reported faster and larger SVR35 responses plus a reported >50% reduction in risk of death versus ruxolitinib; Karyopharm will meet the FDA to discuss the data and potential sNDA/label expansion. PR Newswire: SENTRY met spleen endpoint
• Neutral Sentiment: Company held a scheduled conference call and trading was briefly halted for pending news as the market digested top‑line results and management commentary. Seeking Alpha: SENTRY transcript
• Neutral Sentiment: Analysts trimmed price targets but largely kept bullish ratings — Robert W. Baird cut its target to $15 (still “Outperform”) and HC Wainwright lowered its target to $8 (still “Buy”) — keeping upside expectations but at lower valuations. Benzinga: analyst updates
• Negative Sentiment: SENTRY missed its second co‑primary endpoint (symptom improvement), which raises regulatory/labeling uncertainty and contributed to sharp selling pressure in early trading. Zacks: mixed Phase III data
• Negative Sentiment: Karyopharm announced a $30M private placement with RA Capital (plus ~ $44M if warrants exercised), a dilutive financing that spurred additional selling pressure. PR Newswire: $30M private placement
• Negative Sentiment: Short interest has risen markedly (3.59M shares as of Mar 13, ~19.9% of shares), which can amplify downside momentum as the market digests ambiguous trial outcomes and dilution.
• Negative Sentiment: Market headlines captured both viewpoints — some outlets noted positive trial aspects and a 10% intraday bounce, others highlighted pre‑market slumps and larger percentage drops tied to the financing and mixed read on approval odds. Blockonomi: stock reaction to financing MSN: shares rise 10% after results

About Karyopharm Therapeutics

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.